Journal article 733 views 161 downloads
A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives
Advances in Therapy, Volume: 39, Issue: 1, Pages: 33 - 43
Swansea University Author: Steve Bain
-
PDF | Version of Record
Copyright: The Author(s) 2021. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Download (353.45KB)
DOI (Published version): 10.1007/s12325-021-01927-z
Abstract
Chronic kidney disease (CKD) is a complex disease which affects approximately 13% of the world's population. Over time, CKD can cause renal dysfunction and progression to end-stage kidney disease and cardiovascular disease. Complications associated with CKD may contribute to the acceleration of...
Published in: | Advances in Therapy |
---|---|
ISSN: | 0741-238X 1865-8652 |
Published: |
Springer Science and Business Media LLC
2022
|
Online Access: |
Check full text
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa58735 |
Abstract: |
Chronic kidney disease (CKD) is a complex disease which affects approximately 13% of the world's population. Over time, CKD can cause renal dysfunction and progression to end-stage kidney disease and cardiovascular disease. Complications associated with CKD may contribute to the acceleration of disease progression and the risk of cardiovascular-related morbidities. Early CKD is asymptomatic, and symptoms only present at later stages when complications of the disease arise, such as a decline in kidney function and the presence of other comorbidities associated with the disease. In advanced stages of the disease, when kidney function is significantly impaired, patients can only be treated with dialysis or a transplant. With limited treatment options available, an increasing prevalence of both the elderly population and comorbidities associated with the disease, the prevalence of CKD is set to rise. This review discusses the current challenges and the unmet patient need in CKD. |
---|---|
Keywords: |
Cardiovascular disease, Chronic kidney disease, Diabetic kidney disease, Sodium–glucose co-transporter 2 inhibitors |
College: |
Faculty of Medicine, Health and Life Sciences |
Funders: |
AstraZeneca UK Ltd |
Issue: |
1 |
Start Page: |
33 |
End Page: |
43 |